Maintenance Trials
1. A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Oligometastatic Disease
| ClinicalTrials.gov Identifier: |
NCT01725165 |
This study is ongoing, but not recruiting participants.
The goal of this clinical research study is to learn if surgery or radiation after chemotherapy can help to control NSCLC. The safety of this treatment will also be studied.
Experimental: Local Consolidation Therapy (LCT)
Patients receive local consolidation therapy (LCT) after induction chemotherapy. LCT is radiation, surgery, or both. If assigned to the LCT group, the study doctor will decide if patient has radiation alone, surgery alone, or radiation combined with surgery.
Active Comparator: No Local Consolidation Therapy (LCT)
Patients randomized to the no LCT arm receive maintenance therapy (switch or continuation), or surveillance, based on physician choice after induction chemotherapy. Pemetrexed, bevacizumab, crizotinib (for ALK-mutation positive patients) or erlotinib are recommended as acceptable maintenance agents but other agents may be used at physician discretion.
Ontario
London Health Sciences Centre
London, Ontario, N6A 5W9
2. Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
| ClinicalTrials.gov Identifier: |
NCT02486718 |
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer.
Ontario
Etobicoke, Ontario, M9V 1R8
East York
QC
Laval
3. A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384)
| ClinicalTrials.gov Identifier: |
NCT02713867 |
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung CancerWho Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks.
Ontario
Newmarket, Ontario, L3Y 2P9
Contact: Site 0059
Quebec
Laval, Quebec, H7M 3L9
Contact: Site 0146
Local Institution
Montreal, Quebec, H4J 1C5
Contact: Site 0145
Local Institution
St. Jerome, Quebec, J7Z 5T3
Contact: Site 0060
Local Institution
Quebec,
Contact: Site 0140
4. Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
|
ClinicalTrials.gov Identifier:
|
NCT03703297
|
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy.
Alberta
Research Site Not yet recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Manitoba
Research Site Not yet recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
Ontario
Research Site Not yet recruiting
Hamilton, Ontario, Canada, L8V 5C2
Research Site Not yet recruiting
London, Ontario, Canada, N6A 5W9
Research Site Not yet recruiting
Ottawa, Ontario, Canada, K1H 8L6
Research Site Not yet recruiting
Toronto, Ontario, Canada, M4N 3M5
Quebec
Research Site Not yet recruiting
Montreal, Quebec, Canada, H4A 3J1
5. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU)
| ClinicalTrials.gov Identifier: |
NCT03033511 |
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
British Columbia
British Columbia Cancer Agency / ID# 163721 Recruiting
Surrey, British Columbia, Canada, V3V 1Z2
Ontario
Brampton Civic Hospital / ID# 204425 Recruiting
Brampton, Ontario, Canada, L6R 3J7
R.S. McLaughlin Durham Regional / ID# 170870 Recruiting
Oshawa, Ontario, Canada, L1G 2B9
Princess Margaret / ID# 170868 Recruiting
Toronto, Ontario, Canada, M5G 2M9
Windsor Regional Cancer Centre / ID# 170869 Recruiting
Windsor, Ontario, Canada, N8W 2X3
Quebec
Iucpq / ID# 159530 Recruiting
Sainte-foy, Quebec, Canada, G1V 4G5
6. Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT03137771 |
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Site Public Contact, 780-432-8500
Principal Investigator: Brock J. Debenham
Ontario
London Regional Cancer Program Recruiting
London, Ontario, Canada, N6A 4L6
Ottawa Hospital and Cancer Center-General Campus Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Site Public Contact, 613-761-4395
Principal Investigator: Robert M. MacRae
7. Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4)
| ClinicalTrials.gov Identifier: |
NCT03833154 |
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
Alberta
Research Site Not yet recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Ontario
Research Site Not yet recruiting
London, Ontario, Canada, N6A 5W9
Research Site Not yet recruiting
Toronto, Ontario, Canada, M4N 3M5
Quebec
Research Site Not yet recruiting
Montreal, Quebec, Canada, H2X 3E4
Research Site Not yet recruiting
Montreal, Quebec, Canada, H4A 3J1
8. Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)
| ClinicalTrials.gov Identifier: |
NCT02504372 |
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.
Quebec
Merck Canada
Kirkland, Quebec, Canada, H9H 4M7
Contact: Medical Information Centre/Centre d'information medicale Merck Canada Inc.,
514-428-8600/1-800-567-2594